Using Cardiovascular Disease (CVD) Risk Functions in Public Health and Clinical Trials: The Framingham Experience and Beyond

Ralph B. D’Agostino, Sr., Boston University
Joseph Massaro*, Boston University & Harvard Clinical Research Institute

Abstract

The Framingham Study has been generating cardiovascular disease (CVD) risk functions for over 50 years. These have been used in a number of settings such as treatment guidelines, clinical trials (for example, entry criteria and covariate adjustments) and general consumer evaluations of their own CVD risks. In this paper we will review the history of these functions. We will also present new advances in CVD risk function development which involves generating functions from multiple cardiovascular epidemiological studies.

* Presenting author